Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function: PrE1003, a PrECOG study

Renal insufficiency is common in patients with relapsed multiple myeloma and can often limit choice of therapy. Lenalidomide, a critical agent in the treatment of relapsed multiple myeloma, is renally cleared., This phase I/II trial evaluated the efficacy and safety of lenalidomide with dexamethason...

Descripción completa

Detalles Bibliográficos
Autores principales: Mikhael, Joseph, Manola, Judith, Dueck, Amylou C., Hayman, Suzanne, Oettel, Kurt, Kanate, Abraham S., Lonial, Sagar, Rajkumar, S. Vincent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6127323/
https://www.ncbi.nlm.nih.gov/pubmed/30190454
http://dx.doi.org/10.1038/s41408-018-0110-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6127323/
https://www.ncbi.nlm.nih.gov/pubmed/30190454
http://dx.doi.org/10.1038/s41408-018-0110-7

Ejemplares similares